Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1707502 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $8.04Day +0.88%Mkt cap $792M1Y +13.7%Off 52W high −29.8%Vol (1Y) 80.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,131 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.9% of sh out |
| Days to cover11.2d |
| 13F net flow (QoQ)+7.69% |
| Top-10 13F concentration63.1% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$191.8M |
| ROE−109.9% |
| ROIC−159.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+42.6% |
| 1Y+13.7% |
| 3Y+86.5% |
| 5Y−80.6% |
| Since incept. (ann.)−35.6% |
Total return through 2026-07-29 · series begins 2018-01-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)80.6% |
| Ann. volatility (3Y)103.4% |
| Sharpe (1Y)0.56 |
| Sharpe (3Y)0.68 |
| Max drawdown (1Y)−44.4% |
| Max drawdown (3Y)−82.9% |
| Beta (3Y vs SPY)2.83 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 11.9M | $86M | 12.09% | +0.6% |
| Bain Capital Life Sciences Investors, LLC | 9.8M | $71M | 9.96% | +24.0% |
| RA CAPITAL MANAGEMENT, L.P. | 9.3M | $67M | 9.49% | +60.7% |
| Siren, L.L.C. | 7.7M | $55M | 7.81% | +0.0% |
| Vestal Point Capital, LP | 5.0M | $36M | 5.08% | −14.0% |
| BlackRock, Inc. | 5.0M | $36M | 5.04% | +1.8% |
| JANUS HENDERSON GROUP PLC | 4.0M | $29M | 4.07% | new |
| FMR LLC | 3.6M | $26M | 3.66% | +77.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 101.5% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 8,809,823 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.52 | — | — | — |
| 2025-09-30 | 2025-11-03 | −$0.48 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.42 | — | — | — |
| 2025-03-31 | 2025-05-15 | −$0.59 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 86d) — not company-confirmed.
